Checkpoint Inhibitors in Cancer Care

Special Reports, Immunotherapy (Issue 1), Volume 1, Issue 1

Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.

Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.

In addition to other immunotherapies, Sosman says he is interested innivolumab and ipilimumab in melanoma